BEAM RSI Chart
Last 7 days
-6.5%
Last 30 days
-32.5%
Last 90 days
-8.7%
Trailing 12 Months
-25.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 76.7M | 80.2M | 81.6M | 377.7M |
2022 | 54.1M | 56.4M | 58.7M | 60.9M |
2021 | 13.0M | 25.9M | 38.9M | 51.8M |
2020 | 0 | 0 | 0 | 24.0K |
2019 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 02, 2024 | simon amy | sold | -504,851 | 30.5415 | -16,530 | chief medical officer |
Apr 01, 2024 | simon amy | sold | -229,954 | 32.13 | -7,157 | chief medical officer |
Apr 01, 2024 | burrell terry-ann | sold | -174,926 | 32.12 | -5,446 | chief financial officer |
Apr 01, 2024 | ciaramella giuseppe | sold | -145,632 | 32.12 | -4,534 | president |
Apr 01, 2024 | evans john m. | sold | -581,617 | 32.13 | -18,102 | ceo |
Apr 01, 2024 | bellon christine | sold | -109,240 | 32.12 | -3,401 | chief legal officer |
Mar 31, 2024 | bellon christine | acquired | - | - | 27,500 | chief legal officer |
Mar 31, 2024 | burrell terry-ann | acquired | - | - | 27,500 | chief financial officer |
Mar 31, 2024 | simon amy | acquired | - | - | 27,500 | chief medical officer |
Mar 31, 2024 | ciaramella giuseppe | acquired | - | - | 35,000 | president |
Which funds bought or sold BEAM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 23, 2024 | AMALGAMATED BANK | reduced | -74.81 | -185,000 | 82,000 | -% |
Apr 23, 2024 | FISHMAN JAY A LTD/MI | new | - | 330,400 | 330,400 | 0.04% |
Apr 23, 2024 | Global Retirement Partners, LLC | unchanged | - | 595 | 2,478 | -% |
Apr 22, 2024 | MetLife Investment Management, LLC | added | 5.7 | 170,124 | 1,036,650 | 0.01% |
Apr 22, 2024 | Raymond James Financial Services Advisors, Inc. | added | 9.87 | 72,035 | 287,944 | -% |
Apr 19, 2024 | Sumitomo Mitsui Trust Holdings, Inc. | added | 0.16 | 13,847,200 | 78,034,400 | 0.05% |
Apr 18, 2024 | SteelPeak Wealth, LLC | new | - | 247,966 | 247,966 | 0.01% |
Apr 18, 2024 | ARK Investment Management LLC | reduced | -12.9 | 14,637,400 | 270,339,000 | 1.87% |
Apr 18, 2024 | Piscataqua Savings Bank | unchanged | - | 292 | 1,652 | -% |
Apr 17, 2024 | Clarius Group, LLC | unchanged | - | 352,780 | 2,002,720 | 0.14% |
Unveiling Beam Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Beam Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 41.6B | 6.8B | -8.82 | 6.07 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.14 | 9.91 | ||||
BMRN | 17.2B | 2.4B | 102.64 | 7.11 | ||||
INCY | 11.6B | 3.7B | 19.44 | 3.14 | ||||
MID-CAP | ||||||||
APLS | 6.0B | 396.6M | -11.39 | 15.18 | ||||
BBIO | 4.4B | - | -6.74 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.09 | 12.46 | ||||
ARWR | 2.9B | 240.7M | -9.72 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -44.6 | 3.76 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.96 | 4.48 | ||||
NVAX | 580.8M | 983.7M | -1.07 | 0.59 | ||||
CRBP | 372.9M | 881.7K | -8.36 | 466.16 | ||||
INO | 237.4M | 4.9M | -1.76 | 48.79 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Beam Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 1739.1% | 316,192,000 | 17,193,000 | 20,116,000 | 24,208,000 | 20,037,000 | 15,799,000 | 16,652,000 | 8,432,000 | 6,325,500 | 4,219,000 | 2,112,500 | 6,000 | 6,000 | 6,000 | 162,800 | 319,600 | 476,400 | 633,200 | 790,000 | 498,000 |
Operating Expenses | 46.1% | 183,334,000 | 125,460,000 | 122,264,000 | 123,136,000 | 109,022,000 | 107,102,000 | 98,618,000 | 84,657,000 | 114,553,000 | 70,397,000 | 58,980,000 | 200,379,000 | 40,805,000 | 37,327,000 | 26,291,000 | 28,361,000 | 26,377,000 | 18,030,000 | 17,657,000 | 13,108,000 |
S&GA Expenses | 70.2% | 43,257,000 | 25,410,000 | 24,656,000 | 23,490,000 | 22,681,000 | 21,815,000 | 24,062,000 | 19,247,000 | 17,772,000 | 15,774,000 | 13,403,000 | 10,273,000 | 8,354,000 | 7,502,000 | 6,937,000 | 6,812,000 | 6,160,000 | 5,487,000 | 4,977,000 | 3,929,000 |
R&D Expenses | 40.0% | 140,077,000 | 100,050,000 | 97,608,000 | 99,646,000 | 86,341,000 | 85,287,000 | 74,556,000 | 65,410,000 | 96,781,000 | 54,623,000 | 45,577,000 | 190,106,000 | 32,451,000 | 29,825,000 | 19,354,000 | 21,549,000 | 20,217,000 | 12,543,000 | 12,680,000 | 9,179,000 |
EBITDA Margin | -Infinity% | -0.13 | - | -3.03 | -3.19 | -4.03 | -6.09 | -6.37 | -6.67 | -6.99 | -4.83 | -7.27 | -14.56 | -7,887 | - | - | - | - | - | - | - |
Interest Expenses | -28.6% | 20,000 | 28,000 | 50,000 | 62,000 | 76,000 | 86,000 | 101,000 | 113,000 | 124,000 | 136,000 | 148,000 | 159,000 | 139,000 | 140,000 | - | - | - | - | - | - |
Income Taxes | - | 1,366,000 | - | - | - | 1,000,000 | 2,400,000 | - | - | - | - | - | 159,000 | -422,000 | 140,000 | 148,000 | 134,000 | - | - | - | - |
Earnings Before Taxes | 250.0% | 144,163,000 | -96,088,000 | - | - | -37,349,000 | -81,665,000 | - | - | - | -28,118,000 | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -Infinity% | -0.19 | - | -3.25 | -3.39 | -4.27 | -6.32 | -6.57 | -6.85 | -7.15 | -5.00 | -7.50 | -14.99 | -8,108 | - | - | - | - | - | - | - |
Net Income | 248.6% | 142,797,000 | -96,088,000 | -82,776,000 | -96,460,000 | -38,349,000 | -109,575,000 | -71,950,000 | -69,214,000 | -64,707,000 | -28,118,000 | -76,253,000 | -201,560,000 | -95,464,000 | -34,452,000 | -34,218,000 | -30,458,000 | -27,850,000 | -19,005,000 | -17,861,000 | -13,610,000 |
Net Income Margin | 90.9% | -0.35 | -3.85 | -4.08 | -4.12 | -4.75 | -5.38 | -4.15 | -4.40 | -7.15 | -10.32 | -15.72 | -28.18 | - | - | - | - | - | - | - | - |
Free Cashflow | 234.5% | 131,484,000 | -97,732,000 | -100,847,000 | -115,832,000 | -77,452,000 | -86,283,000 | -73,920,000 | 211,231,000 | -11,539,000 | -2,773,000 | -48,711,000 | -50,056,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
Assets | 13.1% | 1,460 | 1,291 | 1,354 | 1,332 | 1,342 | 1,350 | 1,418 | 1,453 | 1,474 | 1,157 | 893 | 693 | 452 | 278 | 300 | 323 | 156 |
Current Assets | 16.5% | 1,211 | 1,040 | 1,095 | 1,083 | 1,093 | 1,109 | 1,180 | 1,239 | 1,273 | 941 | 678 | 515 | 308 | 209 | 235 | 260 | 95.00 |
Cash Equivalents | 157.9% | 436 | 169 | 226 | 250 | 233 | 157 | 266 | 297 | 560 | 612 | 212 | 97.00 | 177 | 138 | 125 | 126 | 51.00 |
Net PPE | -2.0% | 125 | 128 | 128 | 122 | 116 | 111 | 106 | 94.00 | 84.00 | 72.00 | 64.00 | 52.00 | 39.00 | 29.00 | 26.00 | 25.00 | 24.00 |
Liabilities | -6.5% | 478 | 512 | 542 | 571 | 608 | 636 | 618 | 624 | 648 | 303 | 345 | 271 | 206 | 78.00 | 69.00 | 61.00 | 55.00 |
Current Liabilities | -6.7% | 206 | 220 | 210 | 220 | 224 | 239 | 212 | 219 | 213 | 101 | 129 | 102 | 102 | 47.00 | 39.00 | 31.00 | 29.00 |
Shareholder's Equity | 26.0% | 981 | 779 | 812 | 762 | 733 | 714 | 800 | 829 | 827 | 854 | 549 | 422 | 246 | 200 | 231 | 261 | - |
Retained Earnings | 10.7% | -1,189 | -1,332 | -1,200 | -1,153 | -1,057 | -1,019 | -909 | -837 | -768 | -703 | -675 | -599 | -397 | -302 | -267 | -233 | -203 |
Additional Paid-In Capital | 2.7% | 2,170 | 2,113 | 2,049 | 1,915 | 1,793 | 1,737 | 1,713 | 1,669 | 1,594 | 1,557 | 1,223 | 1,021 | 643 | 502 | 498 | 495 | 2.00 |
Shares Outstanding | 2.8% | 82.00 | 79.00 | 78.00 | 74.00 | 71.00 | 70.00 | 70.00 | 69.00 | 64.00 | 63.00 | 62.00 | 60.00 | - | - | - | - | - |
Float | - | - | - | 2,110 | - | - | - | 2,460 | - | - | - | 6,450 | - | - | - | 982 | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 250.4% | 135 | -89.78 | -84.67 | -109 | -69.19 | -74.50 | -52.28 | 218 | 2.00 | 3.00 | -32.53 | -38.58 | -24.30 | -21.21 | -22.84 | -27.39 | -17.80 | -16.99 | -11.35 | -25.86 |
Share Based Compensation | -12.5% | 23.00 | 26.00 | 26.00 | 24.00 | 22.00 | 22.00 | 22.00 | 18.00 | 16.00 | 13.00 | 10.00 | 5.00 | 7.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Cashflow From Investing | 1058.9% | 98.00 | -10.23 | -41.48 | 25.00 | 113 | -36.17 | -1.26 | -537 | -77.50 | 76.00 | -13.14 | -279 | -81.43 | 35.00 | 23.00 | -76.79 | 17.00 | 14.00 | -95.08 | -2.35 |
Cashflow From Financing | -8.3% | 34.00 | 37.00 | 108 | 98.00 | 32.00 | 2.00 | 22.00 | 56.00 | 22.00 | 321 | 160 | 253 | 130 | 0.00 | -0.78 | 193 | 1.00 | 3.00 | -0.02 | 38.00 |
Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
License and collaboration revenue | $ 377,709 | $ 60,920 | $ 51,844 |
Revenue, Product and Service [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember |
Operating expenses: | |||
Research and development | $ 437,381 | $ 311,594 | $ 387,087 |
General and administrative | 116,813 | 87,805 | 57,222 |
Total operating expenses | 554,194 | 399,399 | 444,309 |
Loss from operations | (176,485) | (338,479) | (392,465) |
Other income (expense): | |||
Change in fair value of derivative liabilities | 7,500 | 23,900 | (1,000) |
Change in fair value of non-controlling equity investments | (18,592) | 20,200 | 17,690 |
Change in fair value of contingent consideration liabilities | 9,740 | 18,904 | 5,146 |
Interest and other income (expense), net | 46,676 | 15,297 | (9) |
Total other income (expense) | 45,324 | 78,301 | 21,827 |
Net loss before income taxes | (131,161) | (260,178) | (370,638) |
Provision for income taxes | (1,366) | (3,410) | |
Loss from equity method investment | (25,500) | ||
Net loss | (132,527) | (289,088) | (370,638) |
Unrealized gain (loss) on marketable securities | 3,034 | (2,380) | (41) |
Comprehensive loss | $ (129,493) | $ (291,468) | $ (370,679) |
Net loss per common share, basic | $ (1.72) | $ (4.13) | $ (5.77) |
Net loss per common share, diluted | $ (1.72) | $ (4.13) | $ (5.77) |
Weighted - average common shares outstanding, basic | 77,151,771 | 70,015,305 | 64,227,676 |
Weighted - average common shares outstanding, diluted | 77,151,771 | 70,015,305 | 64,227,676 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 435,895 | $ 232,767 |
Marketable securities | 753,981 | 845,367 |
Prepaid expenses and other current assets | 21,167 | 14,762 |
Total current assets | 1,211,043 | 1,092,896 |
Property and equipment, net | 124,960 | 115,620 |
Restricted cash | 8,719 | 12,754 |
Operating lease right-of-use assets | 112,846 | 118,513 |
Other assets | 2,146 | 1,931 |
Total assets | 1,459,714 | 1,341,714 |
Current liabilities: | ||
Accounts payable | 1,617 | 9,029 |
Accrued expenses and other current liabilities | 111,664 | 49,912 |
Derivative liabilities | 10,800 | 18,300 |
Current portion of deferred revenue | 68,706 | 135,974 |
Current portion of lease liability | 12,778 | 10,380 |
Total current liabilities | 205,565 | 223,595 |
Long-term lease liability | 159,911 | 168,625 |
Contingent consideration liabilities | 2,723 | 12,463 |
Long-term portion of deferred revenue | 109,888 | 202,179 |
Other liabilities | 298 | 1,378 |
Total liabilities | 478,385 | 608,240 |
Commitments and contingencies (See Note 10, License agreements and Note 11, Collaboration and license agreements) | ||
Stockholders' equity: | ||
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and December 31, 2022, respectively | ||
Common stock, $0.01 par value; 250,000,000 shares authorized, 81,632,496 and 71,277,339 issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 816 | 712 |
Additional paid-in capital | 2,169,798 | 1,792,554 |
Accumulated other comprehensive (loss) income | 604 | (2,430) |
Accumulated deficit | (1,189,889) | (1,057,362) |
Total stockholders' equity | 981,329 | 733,474 |
Total liabilities and stockholders' equity | $ 1,459,714 | $ 1,341,714 |